• 主页
  • 查找结果
  • Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.

Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.

PLoS pathogens (2014-06-20)
Yasushi Itoh, Reiko Yoshida, Shintaro Shichinohe, Megumi Higuchi, Hirohito Ishigaki, Misako Nakayama, Van Loi Pham, Hideaki Ishida, Mitsutaka Kitano, Masahiko Arikata, Naoko Kitagawa, Yachiyo Mitsuishi, Kazumasa Ogasawara, Hideaki Tsuchiya, Takahiro Hiono, Masatoshi Okamatsu, Yoshihiro Sakoda, Hiroshi Kida, Mutsumi Ito, Le Quynh Mai, Yoshihiro Kawaoka, Hiroko Miyamoto, Mari Ishijima, Manabu Igarashi, Yasuhiko Suzuki, Ayato Takada
摘要

Highly pathogenic avian influenza (HPAI) viruses of the H5N1 subtype often cause severe pneumonia and multiple organ failure in humans, with reported case fatality rates of more than 60%. To develop a clinical antibody therapy, we generated a human-mouse chimeric monoclonal antibody (MAb) ch61 that showed strong neutralizing activity against H5N1 HPAI viruses isolated from humans and evaluated its protective potential in mouse and nonhuman primate models of H5N1 HPAI virus infections. Passive immunization with MAb ch61 one day before or after challenge with a lethal dose of the virus completely protected mice, and partial protection was achieved when mice were treated 3 days after the challenge. In a cynomolgus macaque model, reduced viral loads and partial protection against lethal infection were observed in macaques treated with MAb ch61 intravenously one and three days after challenge. Protective effects were also noted in macaques under immunosuppression. Though mutant viruses escaping from neutralization by MAb ch61 were recovered from macaques treated with this MAb alone, combined treatment with MAb ch61 and peramivir reduced the emergence of escape mutants. Our results indicate that antibody therapy might be beneficial in reducing viral loads and delaying disease progression during H5N1 HPAI virus infection in clinical cases and combined treatment with other antiviral compounds should improve the protective effects of antibody therapy against H5N1 HPAI virus infection.

材料
货号
品牌
产品描述

Sigma-Aldrich
水, Nuclease-Free Water, for Molecular Biology
Sigma-Aldrich
水, suitable for HPLC
Sigma-Aldrich
水, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
水, HPLC Plus
Sigma-Aldrich
水, deionized
Supelco
水, suitable for ion chromatography
Sigma-Aldrich
水, for molecular biology, sterile filtered
Sigma-Aldrich
水, for embryo transfer, sterile-filtered, BioXtra, suitable for mouse embryo cell culture
纯水密度标准物质RM, 0.9982 g/mL(20 °C), UKAS ISO/IEC17025 and ISO Guide 34 certified, density: 0.9982 g/mL at 20 °C, density: 0.9970 g/mL at 25 °C
Supelco
水, for TOC analysis
Supelco
水, ACS reagent, for ultratrace analysis
Sigma-Aldrich
水, BioPerformance Certified
Sigma-Aldrich
水, PCR Reagent
Sigma-Aldrich
水, for cell biology, sterile ultrafiltered
Sigma-Aldrich
水, ACS reagent
Sigma-Aldrich
水, tested according to Ph. Eur.
Sigma-Aldrich
E-Toxate 水, endotoxin, free
Sigma-Aldrich
低氘水, ≤1 ppm (Deuterium oxide)
Supelco
水, for HPCE, for luminescence, suitable for UV/Vis spectroscopy
环磷酰胺, European Pharmacopoeia (EP) Reference Standard
Supelco
密度标准品 998kg/m3, H&D Fitzgerald Ltd. Quality
环孢素, European Pharmacopoeia (EP) Reference Standard
水, UKAS ISO/IEC17025 and ISO Guide 34 certified, density: 0.9982 g/mL at 20 °C, density: 0.9970 g/mL at 25 °C
Sigma-Aldrich
(±)-CPP, solid
Sigma-Aldrich
水-16O, ≥99.94 atom % 16O
系统适用性试验用环孢素, European Pharmacopoeia (EP) Reference Standard